Pape L, Ehrich J H H, Offner G
Department of Pediatric Nephrology, Medical School of Hannover, Hannover, Germany.
Clin Transplant. 2004 Oct;18(5):576-9. doi: 10.1111/j.1399-0012.2004.00229.x.
Mycophenolate mofetil (MMF) has the potential of decreasing acute rejection episodes early following renal transplantation. Pharmocokinetic monitoring of mycophenolic acid (MPA) trough levels is performed by many centers. MMF has also proved successful in improving long-term graft function in patients with chronic allograft nephropathy (CAN). However, no data for long-term monitoring of MPA in children have yet been published.
MMF therapy with a dose of 600 mg/m2 twice daily was initiated in 42 children (median age 9.4 yr, range 1.4-15.1) after a median period of 3.8 yr (range 1.0-10.6) post-transplantation-- according to significant increases in serum creatinine. CAN was diagnosed by renal biopsy and the amount of fibrosis was quantified with PicroSiriusRed staining. MMF therapy was combined with ciclosporin A and prednisolone. MPA-C0-levels, measured by high-pressure liquid chromatography, were tested every 3 months. In 12 children a full MPA area under the curve concentration (AUC) was measured. The glomerular filtration rate (GFR) was calculated at the start of MMF therapy and 2 yr later.
After initiation of MMF, the calculated GFR did not decrease further in 22 children and mean GFR remained stable for 2 yr in the whole study group. There was a significant correlation between MPA levels 75 min after administration and the full AUC (r = 0.94, p < 0.001) but no correlation between trough levels and AUC (r = -0.07, p > 0.05). The mean MPA trough level was 2.8 +/- 1.3 ng/mL. The intra-individual coefficient of variation was 2.6 +/- 1.4. There was no correlation between mean MPA trough levels and GFR development after 2 yr (r = 0.03, p > 0.05). In children with an MPA level below 1.2 mg/L (n = 5), the mean GFR decline was no different to those with a higher level (p > 0.05).
Drug monitoring of MPA trough levels had no impact on long-term graft function in kidney recipients. MPA levels taken 75 min after administration showed a high correlation with MPA-AUC whereas C0-levels did not correlate. The value of C75 drug measurements for monitoring renal allograft survival will have to be judged in future studies.
霉酚酸酯(MMF)有降低肾移植术后早期急性排斥反应发生率的潜力。许多中心都开展了霉酚酸(MPA)谷浓度的药代动力学监测。MMF在改善慢性移植肾肾病(CAN)患者的长期移植肾功能方面也已被证明是成功的。然而,关于儿童MPA长期监测的数据尚未发表。
42名儿童(中位年龄9.4岁,范围1.4 - 15.1岁)在移植术后中位时间3.8年(范围1.0 - 10.6年),根据血清肌酐显著升高,开始接受剂量为600 mg/m²、每日两次的MMF治疗。通过肾活检诊断CAN,并用苦味酸天狼星红染色对纤维化程度进行定量。MMF治疗联合环孢素A和泼尼松龙。每3个月通过高压液相色谱法检测MPA - C0水平。在12名儿童中测量了MPA曲线下面积浓度(AUC)的完整值。在MMF治疗开始时和2年后计算肾小球滤过率(GFR)。
开始MMF治疗后,22名儿童计算出的GFR未进一步下降,整个研究组的平均GFR在2年内保持稳定。给药后75分钟时的MPA水平与完整AUC之间存在显著相关性(r = 0.94,p < 0.001),但谷浓度与AUC之间无相关性(r = -0.07,p > 0.05)。MPA平均谷浓度为2.8 ± 1.3 ng/mL。个体内变异系数为2.6 ± 1.4。2年后MPA平均谷浓度与GFR变化之间无相关性(r = 0.03,p > 0.05)。MPA水平低于1.2 mg/L的儿童(n = 5),其平均GFR下降与MPA水平较高的儿童无差异(p > 0.05)。
MPA谷浓度的药物监测对肾移植受者的长期移植肾功能无影响。给药后75分钟时的MPA水平与MPA - AUC高度相关,而C0水平则无相关性。C75药物测量值对监测肾移植存活情况的价值有待未来研究判定。